TABLE 1.
Demographic and clinical characteristics at baseline by treatment arm
| Treatment modalities | ||||||
|---|---|---|---|---|---|---|
| Characteristic | Placebo (N = 80) | All PE‐treated (N = 242) | Low albumin (N = 78) | Low albumin + IVIG (N = 86) | High albumin + IVIG (N = 78) | Total (N = 322) |
| Age (years), mean (SD) | 68.4 (8.4) | 69.2 (7.4) | 68.5 (7.5) | 69.5 (6.9) | 69.5 (7.9) | 69.0 (7.7) |
| Age group (n, %) | ||||||
| < 65 | 29 (36.3) | 65 (26.9) | 26 (33.3) | 17 (19.8) | 22 (28.2) | 94 (29.2) |
| 65‐75 | 33 (41.3) | 124 (51.2) | 37 (47.4) | 52 (60.5) | 35 (44.9) | 157 (48.8) |
| > 75 | 18 (22.5) | 53 (21.9) | 15 (19.2) | 17 (19.8) | 21 (26.9) | 71 (22.0) |
| Sex (n, %) | ||||||
| Male | 44 (55.0) | 104 (43.0) | 35 (44.9) | 38 (44.2) | 31 (39.7) | 148 (46.0) |
| Female | 36 (45.0) | 138 (57.0) | 43 (55.1) | 48 (55.8) | 47 (60.3) | 174 (54.0) |
| BMI (Kg/m2), mean (SD) | 26.8 (4.3) | 26.9 (4.6) | 27.0 (4.8) | 27.1 (4.0) | 26.5 (5.0) | 26.9 (4.5) |
| Time since diagnosis of AD (years), mean (SD) | 2.5 (2.3) | 2.4 (2.4) | 2.2 (2.4) | 2.5 (2.3) | 2.4 (2.6) | 2.4 (2.4) |
| MMSE score, mean (SD) | 21.7 (2.6) | 21.7 (2.6) | 21.2 (2.4) | 22.1 (2.6) | 21.4 (2.6) | 21.6 (2.6) |
| Severity of AD (n, %) | ||||||
| Moderate (MMSE 18‐21) | 36 (45.0) | 117 (48.3) | 46 (59.0) | 37 (43.0) | 42 (53.8) | 161 (50.0) |
| Mild (MMSE 22‐26) | 44 (55.0) | 125 (51.7) | 32 (41.0) | 49 (57.0) | 36 (46.2) | 161 (50.0) |
| AD medication (n, %) | ||||||
| CEIs | 56 (70.0) | 164 (67.7) | 55 (70.5) | 50 (58.1) | 59 (75.6) | 220 (68.3) |
| Memantine | 7 (8.8) | 36 (14.9) | 13 (16.7) | 14 (16.3) | 9 (11.5) | 43 (13.4) |
| CEIs + memantine | 16 (20.0) | 40 (16.5) | 8 (10.3) | 22 (25.6) | 10 (12.8) | 56 (17.4) |
| None | 1 (1.3) | 2 (0.8) | 2 (2.6) | 0 | 0 | 3 (0.9) |
| APOE Ɛ4 | ||||||
| N | 77 | 231 | 74 | 83 | 74 | 308 |
| Carriers (n, %) | 34 (44.2) | 120 (51.9) | 47 (63.5) * | 40 (48.2) | 33 (44.6) | 154 (50.0) |
| Non‐carriers (n, %) | 43 (55.8) | 111 (49.1) | 27 (36.5) | 43 (51.8) | 41 (55.4) | 154 (50.0) |
| CSF Aβ42 | ||||||
| N | 71 | 226 | 74 | 77 | 75 | 297 |
| pg/mL, median (IQR) | 551 (380‐810) | 505 (431‐700) | 502 (436‐618) | 509 (399‐730) | 505 (407‐822) | 515 (426‐737) |
Abbreviations: AD, Alzheimer's disease; BMI, body mass index; CEI, cholinesterase inhibitor; CSF, cerebrospinal fluid; IQR, Interquartile range; IVIG, intravenous immunoglobulin; MMSE, Mini‐Mental State Examination; PE, plasma exchange; SD, standard deviation.
*
P = .02.